NASDAQ:IONSIonis Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ionis Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $51.46 +2.95 (+6.08 %) (As of 04/7/2020 04:37 AM ET) Add Compare Share Today's Range$48.16Now: $51.46▼$51.7450-Day Range$41.60MA: $51.07▼$61.7352-Week Range$39.32Now: $51.46▼$86.58Volume939,344 shsAverage Volume1.02 million shsMarket Capitalization$7.16 billionP/E Ratio24.86Dividend YieldN/ABeta1.76 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardio metabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardio metabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hyper tension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease, and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.Read More Beat the Market (BTM) Rank™ 4.3 Analyst's Opinion Consensus RatingIonis Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 7 buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $74.46, Ionis Pharmaceuticals has a potential upside of 44.7% from its current price of $51.46.Amount of Analyst CoverageIonis Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.3 Community Rank Outperform VotesIonis Pharmaceuticals has received 619 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIonis Pharmaceuticals has received 737 “underperform” votes. (Add your “underperform” vote.)Community SentimentIonis Pharmaceuticals has received 54.35% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote “Outperform” if you believe IONS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,613,917.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions86.60% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to decrease by -407.69% in the coming year, from ($0.13) to $0.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is 24.86, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 11.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is 24.86, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.92.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 4.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.51 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IONS Previous Symbol CUSIP46433010 CIK874015 Webhttp://www.ionispharma.com/ Phone760-931-9200Debt Debt-to-Equity Ratio0.47 Current Ratio9.97 Quick Ratio9.90Price-To-Earnings Trailing P/E Ratio24.86 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.12 billion Price / Sales6.38 Cash Flow$2.58 per share Price / Cash Flow19.96 Book Value$11.98 per share Price / Book4.30Profitability EPS (Most Recent Fiscal Year)$2.08 Net Income$303.26 million Net Margins26.09% Return on Equity22.23% Return on Assets11.32%Miscellaneous Employees737 Outstanding Shares139,220,000Market Cap$7.16 billion Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive IONS News and Ratings via Email Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:IONS Rates by TradingView Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions How has Ionis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IONS shares have increased by 4.7% and is now trading at $51.46. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Ionis Pharmaceuticals? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ionis Pharmaceuticals. When is Ionis Pharmaceuticals' next earnings date? Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Ionis Pharmaceuticals. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted its earnings results on Wednesday, February, 26th. The company reported $1.28 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.91 by $0.37. The company earned $494 million during the quarter, compared to the consensus estimate of $407.05 million. Ionis Pharmaceuticals had a return on equity of 22.23% and a net margin of 26.09%. The company's revenue was up 157.3% on a year-over-year basis. During the same period last year, the firm posted $2.21 earnings per share. View Ionis Pharmaceuticals' earnings history. What guidance has Ionis Pharmaceuticals issued on next quarter's earnings? Ionis Pharmaceuticals issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, February, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $700 million, compared to the consensus revenue estimate of $814.68 million. What price target have analysts set for IONS? 14 Wall Street analysts have issued 12 month price targets for Ionis Pharmaceuticals' shares. Their forecasts range from $48.00 to $120.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $74.46 in the next twelve months. This suggests a possible upside of 44.7% from the stock's current price. View analysts' price targets for Ionis Pharmaceuticals. Has Ionis Pharmaceuticals been receiving favorable news coverage? Press coverage about IONS stock has been trending very negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ionis Pharmaceuticals earned a news impact score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutIonis Pharmaceuticals. Who are some of Ionis Pharmaceuticals' key competitors? Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Repligen (RGEN) and Exelixis (EXEL). What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), Alibaba Group (BABA), BlackRock (BLK), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Gilead Sciences (GILD), NVIDIA (NVDA), Intercept Pharmaceuticals (ICPT) and Skyworks Solutions (SWKS). Who are Ionis Pharmaceuticals' key executives? Ionis Pharmaceuticals' management team includes the following people: Dr. Stanley T. Crooke, Founder, Chairman, CEO & Pres (Age 74)Dr. Brett P. Monia, Founder, COO, Sr. VP of Translational Medicine & Director (Age 58)Ms. Elizabeth L. Hougen, Sr. VP of Fin. & CFO (Age 57)Dr. Richard S. Geary, Sr. VP of Devel. (Age 61)Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65) What is Ionis Pharmaceuticals' stock symbol? Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS." How do I buy shares of Ionis Pharmaceuticals? Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ionis Pharmaceuticals' stock price today? One share of IONS stock can currently be purchased for approximately $51.46. How big of a company is Ionis Pharmaceuticals? Ionis Pharmaceuticals has a market capitalization of $7.16 billion and generates $1.12 billion in revenue each year. The company earns $303.26 million in net income (profit) each year or $2.08 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe. View additional information about Ionis Pharmaceuticals. What is Ionis Pharmaceuticals' official website? The official website for Ionis Pharmaceuticals is http://www.ionispharma.com/. How can I contact Ionis Pharmaceuticals? Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200. This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: What is the Bid-Ask Spread?
